At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 720 enrolled
Drug / intervention
Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-inferiority Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A Using Different Formulations.
In Brief
A Phase 2 clinical trial evaluating Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A) and Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A) for Influenza. Completed, enrolled 720 participants across 3 sites.
Detailed Summary
The purpose of this study is to show the non-inferiority of different formulations of GlaxoSmithKline Biologicials' influenza vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesEstonia
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMar 2008
Primary CompletionApr 2008
TodayJul 2026
First PostedMar 11, 2008
Enrollment StartMar 3, 2008
Primary CompletionApr 11, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 18.3 years ago
Interventions
Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)biological
Intramuscular administration, 1 dose
Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)biological
Intramuscular administration, 1 dose